<DOC>
	<DOC>NCT02762370</DOC>
	<brief_summary>This study is a double-blind, randomized, parallel group comparison of the effects of FX006 and Triamcinolone Acetonide Injectable Suspension, USP (referred to as TCA IR in the protocol) on blood glucose in patients with osteoarthritis of the knee and Type 2 diabetes mellitus.</brief_summary>
	<brief_title>Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes</brief_title>
	<detailed_description>This study is a double-blind, randomized, parallel group, single-dose study design. The study will be conducted in male and female patients ≥ 40 years of age with osteoarthritis of the knee and Type 2 diabetes mellitus. Approximately 36 patients will be randomized to one of the two treatment groups (1:1) and treated with a single intra-articular (IA) injection of: - 40 mg FX006 or - 40 mg TCA IR Blood glucose levels will be evaluated for a total of 3 weeks (one week prior to injection and two weeks post IA injection) using a continuous glucose monitoring device. Following randomization and IA injection, patients will return for follow up visits at Day 8, Day 15 and Week 6/Day 43.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<criteria>Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions Male or female ≥40 years of age Type 2 diabetes mellitus for at least 1 year prior to Screening and not managed with injectable agents (e.g. insulin or insulin analogs, exenatide, pramlintide, liraglutid) Currently treated with 1 or 2 oral agents for diabetes, with stable doses for at least 2 months HbA1c ≥6.5% and ≤ 9.0% Currently meets ACR Criteria (clinical or radiological) for OA. Symptoms associated with OA of the knee for ≥ 6 months prior to Screening Index knee pain on most days (&gt;15) over the last month (as reported by the patient) Body mass index (BMI) ≤ 40 kg/m2 Willingness to abstain from use of protocolspecified restricted medications during the study Willingness to wear a CGM device uninterrupted for 24 hours per day throughout the study, remain with receiving range and comply with calibration requirements Accustomed to using a Standard Blood Glucose Measuring device by finger stick Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or arthritis associated with inflammatory bowel disease History of infection in the index knee joint Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening Presence of surgical hardware or other foreign body in the index knee Unstable joint (such as a torn anterior cruciate ligament) within 12 months of screening IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening IV or IM corticosteroids (investigational or marketed) within 3 months of Screening Oral corticosteroids (investigational or marketed) within 1 month of Screening Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening Any other IA investigational drug/biologic within 6 months of Screening Prior use of FX006 Use of acetaminophen, or acetaminophen containing products Current use of a continuous glucose monitoring device Women of childbearing potential not using effective contraception or who are pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
	<keyword>Pain</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Intra-articular</keyword>
	<keyword>Injection</keyword>
</DOC>